MedPath

efficacy of Unani herbal formulation in the treatment of piles

Phase 2
Completed
Conditions
Bawaseer (Haemorrhoids)
Registration Number
CTRI/2017/09/009744
Lead Sponsor
Luqman unani medical college hospital and research centre
Brief Summary

30 diagnosed cases of *Bawaseer* (Hemorrhoids) will be randomly allocated either to test (n=15) or control group (n=15). Patients will be blinded for the study. In the test group; 500mg hab of the polyherbal formulation will be give morning and evening for 30 days orally. In the control drug 2 Capsule Hamdoroid will be given orally morning and evening for 30 days.The follow up of patients will be done at 15 days interval. Two follow up during treatment and two after treatment will be done. Assessment of subjective parameters will be done on each visit and objective parameters will be assessed before and after treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

1.Patients of either gender, aged ≥18 years, with hemorrhoids (Grades Ι & П) confirmed by proctoscopy.

Exclusion Criteria
  • 1.Patients suffering from systemic diseases and severe anaemia.
  • 2.Hemorrhoids with fistula in anal canal confirmed by proctoscopic examination.
  • 3.Pregnancy and lactation.
  • 4.Patients currently using other anti-hemorrhoid drugs.
  • 5.Female patients with menstrual disorders.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in subjective and objective parameters2 months
Secondary Outcome Measures
NameTimeMethod
Change in Hb%1 month

Trial Locations

Locations (1)

Luqman Unani Medical College Hospital and Research Centre

🇮🇳

Bijapur, KARNATAKA, India

Luqman Unani Medical College Hospital and Research Centre
🇮🇳Bijapur, KARNATAKA, India
Dr Iqbalpatel Khanwale
Principal investigator
9590747736
dr.iqbalpatel1689@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.